Diagnosis and treatment of tumor-suppressor associated disorders
Methods are provided for detecting a cell proliferative disorder associated with TSLC1 by contacting a proliferating cell of a subject suspected of having the disorder with a reagent that detects TSLC1 and detecting the level of TSLC1 in the proliferating cell. TSLC1 is a single gene whose expression is reduced or absent in A549 and some other NSCLC, hepatocellular carcinoma and pancreatic cancer cell lines. It has further been discovered that TSLC1 expression or suppression is perfectly correlated with promoter methylation state. Restoration of TSLC1 expression to normal or higher levels is sufficient by itself to suppress tumor formation. The invention further provides methods of treating such disorders by contacting cells of a patient suffering from the disorder with a therapeutically effective amount of a reagent that modulates TSLC1 level in the proliferating cells.
1. A method of determining whether a subject has a cell proliferative disorder associated with tumor suppressor lung cancer 1 (TSLC 1), said method comprising contacting a nucleic acid sample of the subject with a reagent that detects the level of TSLC1 polynucleotide and determining the level of the TSLC1 polynucleotide as compared with the level in a comparable healthy cell, wherein a difference in the level of the TSLC1 polynucleotide between the sample from the subject and the healthy cell is indicative of a proliferative disorder in the subject.
2. A method of detecting a cell proliferative disorder associated with tumor suppressor lung cancer 1 (TSLC1) in a subject in need thereof, said method comprising contacting a cell component of a proliferating cell of the subject with a reagent that detects the level of the cell component in the proliferating cell and determining a modification in the level of the cell component in the proliferating cell as compared with a comparable healthy cell, wherein the cell component indicates the level of TSLC1 in the cell and the modification indicates the disorder associated with TSLC1, wherein the modification is a decrease in the level of TSLC1.
3. The method of claim 1 , wherein the nucleic acid is DNA.
4. The method of claim 1 , wherein the nucleic acid is RNA.
5. The method of claim 4 , wherein the RNA is mRNA.
6. The method of claim 1 , wherein the nucleic acid encodes the TSLC1.
7. The method of claim 1 , wherein the reagent is a nucleic acid probe or primer that binds to the TSLC1 polynucleotide.
8. The method of claim 7 , wherein the nucleic acid probe or primer has a detectable label.
9. The method of claim 7 , wherein the nucleic acid probe has a nucleotide sequence selected from the group consisting of:
a) a polynucleotide sequence as set forth in SEQ ID NO:17;
b) a polynucleotide having at least 70% identity to the polynucleotide of a);
c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide comprising at least 15 bases of a polynucleotide of a); and
e) a polynucleotide comprising at least 15 bases of a polynucleotide of b), wherein the nucleic acid probe detects the polynucleotide of a).
10. The method of claim 1 , wherein the disorder is cancer.
11. A method of detecting a cell proliferative disorder in a subject in need thereof, said method comprising contacting nucleic acid of a test cell from a subject with a reagent that detects the level of a TSLC1 polynucleotide and detecting a difference in the level of the TSLC1 polynucleotide as compared to that of a comparable normal cell; wherein the difference in the level of the TSLC1 polynucleotide between the sample from the subject and the normal cell is indicative of a cell proliferative disorder.
12. The method of claim 11 , wherein the nucleic acid is DNA.
13. The method of claim 11 , wherein the nucleic acid is RNA.
14. The method of claim 13 , wherein the RNA is mRNA.
15. The method of claim 11 , wherein the reagent is a nucleic acid probe or primer that binds to TSLC1.
16. The method of claim 11 , wherein subject has loss of heterozygosity of 11q23 chromosome.
17. The method of claim 11 , wherein the difference in the level of the TSLC1 polynucleotide indicates reduced production of TSLC1 in the test cell as compared to the comparable normal cell.
18. The method of claim 1 , wherein the difference in the level of the TSLC1 polynucleotide indicates reduced production of TSLC1 in the test cell as compared to the comparable normal cell.
19. The method of claim 1 , wherein determining the level of the TSLC1 polynucleotide comprises Southern blotting, Northern blotting, RNase protection, PCR or in situ hybridization.
20. The method of claim 10 , wherein the cancer is lung, liver or pancreatic cancer.
21. The method of claim 20 , wherein the lung cancer is human non-small cell lung cancer.
22. The method of claim 20 , wherein the liver cancer is hepatocellular carcinoma.
23. The method of claim 11 , wherein the cell proliferative disorder lung cancer, liver cancer or pancreatic cancer.
24. The method of claim 22 , wherein the lung cancer is human non-small cell lung cancer.
25. The method of claim 22 , wherein the liver cancer is hepatocellular carcinoma.